Prescriber Scope of Practice for Depression in Pennsylvania

You’re a psychiatrist or PMHNP considering telehealth. Maybe you’re already seeing patients remotely and want to make sure you’re prescribing legally. Or you’re thinking about joining a platform like Klarity to expand your practice across state lines. Either way, you’ve got questions: Can I prescribe antidepressants via video? What about Adderall for a patient with comorbid ADHD? Do I need to see them in person first?

The short answer: Yes, psychiatrists and PMHNPs can prescribe depression medications via telehealth—including controlled substances—through at least December 31, 2026, thanks to federal COVID-era flexibilities that have been extended multiple times. Most depression medications aren’t controlled substances anyway (SSRIs, SNRIs, bupropion), so you can prescribe them via telemedicine in any state where you’re licensed, following the same standard of care as in-person visits.

But the details matter. Federal DEA rules, state prescribing laws, and your scope of practice (especially if you’re a PMHNP) all affect what you can do. Let’s break down exactly what’s legal, what’s changing, and what you need to know to practice confidently—and compliantly—via telehealth.

Federal DEA Rules: The Ryan Haight Act & COVID Extensions (Through 2026)

The baseline federal rule is the Ryan Haight Online Pharmacy Consumer Protection Act (2008), which says you can’t prescribe a controlled substance via telemedicine without first conducting an in-person medical evaluation—unless an exception applies.

During COVID, that rule was suspended. The DEA and HHS invoked a public health emergency exception, allowing providers to prescribe controlled substances (Schedule II–V) to patients they’d never met in person, as long as the telehealth visit met the standard of care. When the public health emergency officially ended in May 2023, everyone expected those flexibilities to expire.

They didn’t. The DEA has extended them four times. The latest extension runs through December 31, 2026. That means:

• You can initiate treatment for a new patient via telehealth (video or phone, depending on state law) and prescribe controlled substances without an in-person visit
• This applies to Schedule II drugs (Adderall, Ritalin, methylphenidate) and Schedule III–V (benzodiazepines, Ambien, ketamine)
• You still need a valid DEA registration, must check your state’s prescription drug monitoring program (PDMP), and follow all other standard prescribing requirements

For depression treatment specifically, this mostly matters when you’re managing comorbid conditions: anxiety (benzodiazepines), ADHD (stimulants), or treatment-resistant depression (esketamine, though that has separate REMS requirements). The core antidepressants—SSRIs, SNRIs, TCAs, MAOIs, bupropion, mirtazapine—are not controlled substances, so the Ryan Haight Act doesn’t apply to them at all.

What Happens After 2026?

The DEA is working on permanent rules. In January 2025, they proposed a Special Registration for Telemedicine program:

• Schedule III–V: Any provider prescribing these via telehealth would apply for a special telemedicine registration (in addition to their regular DEA number)
• Schedule II: Only certain specialists—psychiatrists (board-certified), hospice/palliative care physicians, nursing home physicians, and pediatric specialists—could apply for an ‘Advanced Telemedicine Prescribing’ registration to prescribe Schedule II drugs without an in-person exam

If this rule is finalized as proposed, psychiatrists will have explicit federal authority to prescribe stimulants and other Schedule II medications via telehealth for psychiatric conditions—no in-person visit required. PMHNPs and PAs are notably not included in the advanced registration category for Schedule II, which means they may face more restrictions post-2026 (or may need to work under a psychiatrist who has the special registration).

The DEA is taking public comments and expects to finalize these rules before the current extension expires. For now, you can continue operating under the COVID-era flexibility, but stay tuned for updates in late 2026.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Scope of Practice: Psychiatrists vs PMHNPs

Psychiatrists (MD/DO)

Your scope of practice for treating depression is essentially unlimited:

• You can diagnose and treat any psychiatric condition
• You can prescribe any medication (controlled or non-controlled)
• You don’t need supervision or collaboration in any state
• You can practice via telehealth in any state where you hold a medical license

The only regulatory limitations are the same ones that apply to all physicians: you need a state medical license where the patient is located, a DEA registration if prescribing controlled substances, and you must follow standard-of-care guidelines.

Psychiatric Mental Health Nurse Practitioners (PMHNPs)

Your scope varies significantly by state. All PMHNPs are trained to diagnose and treat mental health conditions, including depression, and to prescribe medications. But whether you can do so independently depends on your state’s nurse practice act:

Full Practice Authority (FPA) States:

• California (as of 2024, after completing AB 890 requirements—3+ years experience, transition-to-practice training)
• New York (after 3,600 hours of practice)
• Illinois (after 4,000 hours + additional education/training)
• Many other states (Oregon, Washington, Colorado, etc.)

In FPA states, you can see patients, diagnose, and prescribe (including controlled substances) without a physician’s involvement. You’ll need your own DEA number and state controlled substance license, but there’s no collaborative agreement requirement.

Restricted Practice States:

• Texas – Must have a written Prescriptive Authority Agreement with a physician; monthly meetings required
• Florida – Psychiatric NPs are excluded from autonomous practice (only primary care NPs qualify); you need a supervising physician and signed protocol
• Pennsylvania – Collaborative agreement required; no FPA legislation passed yet

In these states, you’ll need a collaborating or supervising physician (often a psychiatrist) on paper. The physician doesn’t have to be on your video calls, but they must be available for consultation, and the relationship must be documented per state board rules.

Practical implications for telehealth:

• In FPA states, you can join a platform like Klarity and practice independently
• In restricted states, the platform may need to pair you with a supervising psychiatrist, or you’ll need to arrange your own collaboration before you can see patients

Controlled substance prescribing: Even in FPA states, there are sometimes extra hoops for Schedule II drugs. For example, Illinois requires FPA APRNs to have a physician consultation process for ongoing Schedule II opioid prescriptions (not typically relevant for psych, but worth knowing). Some states limit NP Schedule II prescribing to specific settings (e.g., Texas restricts it to hospitals/hospice for outpatient APRNs).

Bottom line: Know your state’s rules. If you’re in California, New York, or Illinois and meet the experience requirements, you have essentially the same prescribing authority as a psychiatrist (within your scope). If you’re in Texas, Florida, or Pennsylvania, you’ll need a physician collaborator.

State-by-State Telehealth Prescribing Rules

Federal law sets the floor, but states can add requirements. Here’s what you need to know in the major markets:

California

Telehealth Prescribing: No state law requiring an in-person exam. You can establish a patient relationship via video and prescribe anything—antidepressants, benzodiazepines, stimulants—as long as the telehealth encounter meets the standard of care.

NP Independence: As of 2024, experienced PMHNPs (3+ years, completed transition-to-practice under AB 890) can practice independently without physician supervision. This is a recent change—California used to require collaboration.

Licensing: You must have a California medical or NP license. California is not part of the Interstate Medical Licensure Compact (IMLC), so out-of-state providers need to apply for a full CA license (no telehealth-specific shortcut).

Key Regulatory Notes:

• Check CURES (California’s PDMP) before prescribing controlled substances
• Telehealth parity laws mean insurers must cover tele-mental health the same as in-person
• Audio-only visits are allowed for mental health in some cases (expanded during COVID and maintained for certain payers)

Economics: California has a large patient base, high demand for psychiatric services (especially in rural/Inland areas), and progressive telehealth policies. Patient acquisition cost via DIY marketing (Google Ads, SEO, directories) typically runs $200–500+ per booked patient when you factor in ad spend, agency fees, and time. Platforms like Klarity eliminate that upfront spend—you pay a standard per-appointment listing fee only when a pre-qualified patient books with you.

Texas

Telehealth Prescribing: You can establish a valid patient relationship via live video (audio-visual telemedicine). Phone-only is generally insufficient for new patients.

Controlled Substances: Texas has a specific prohibition on treating chronic pain with controlled substances via telemedicine unless you’ve seen the patient in person (or via video) within the last 90 days. This rule doesn’t affect psychiatric practice directly—treating depression, anxiety, or ADHD via telehealth is fine. But if you’re managing a patient with depression and chronic pain who needs opioids or long-term benzodiazepines, be cautious (may require in-person component or specialist pain management referral).

NP Scope: Texas does not allow NP independence. You need a Prescriptive Authority Agreement with a physician, and the physician must be available for consultation. For PMHNPs, this usually means having a supervising psychiatrist.

Licensing: Full Texas license required. Texas is an IMLC member (for physicians), so out-of-state MDs can get a TX license more easily.

Key Regulatory Notes:

• E-prescribing is standard; use Texas PMP for controlled substances
• Texas has 246 of 254 counties designated as mental health shortage areas—huge demand for telepsychiatry
• State medical board is strict on documentation; make sure your chart notes justify the telemedicine modality and prescribing decisions

Economics: Large patient population, but the chronic pain prescribing rule and NP supervision requirements add administrative complexity. If you’re a psychiatrist, Texas is a straightforward high-volume opportunity via telehealth. If you’re a PMHNP, you’ll need to partner with a Texas-licensed psychiatrist (which Klarity can help facilitate if you’re on the platform).

Florida

Telehealth Prescribing: Florida allows out-of-state providers to register to provide telehealth services without obtaining a full Florida license (Florida Statute §456.47). This is a unique feature—few states offer this.

Controlled Substances: Florida law prohibits prescribing Schedule II drugs via telehealth except for:

1. Psychiatric disorders
2. Inpatient hospital treatment
3. Hospice care
4. Nursing home residents

For depression and ADHD treatment, the psychiatric disorder exception applies—you can prescribe Adderall, Ritalin, or other Schedule II stimulants via telehealth to Florida patients as long as it’s part of a legitimate psychiatric treatment plan. Schedule III–V (benzodiazepines, Ambien, etc.) have no special restrictions.

NP Scope: Florida’s 2020 NP independence law excluded psychiatric NPs. Only primary care NPs (family medicine, internal medicine) can practice autonomously. PMHNPs must have a supervising physician and a signed protocol filed with the Florida Board of Nursing.

Licensing: Either a full Florida license or an Out-of-State Telehealth Registration. Florida is an IMLC member for physicians.

Key Regulatory Notes:

• Check Florida’s PDMP (E-FORCSE) before prescribing controlled substances
• Document that Schedule II prescriptions are for a psychiatric indication (to satisfy the statutory exception)
• If using the telehealth registration route, you cannot practice in-person in Florida or open a physical office

Economics: Florida has a large, growing population and provider shortages in many areas (especially outside Miami/Tampa/Orlando metro). The telehealth registration option makes Florida an attractive market for out-of-state psychiatrists. Patient acquisition via traditional marketing is expensive here ($300–600+ per qualified patient), so platforms that deliver pre-qualified leads offer strong ROI.

New York

Telehealth Prescribing: No state restrictions beyond standard of care. You can establish a patient relationship via video (or even audio-only for mental health, per COVID-era policies that have been extended).

NP Independence: Experienced NPs (3,600+ hours of practice) can practice without a written collaborative agreement or physician supervision (as of 2022). This effectively gives PMHNPs full practice authority after a couple of years.

Licensing: Full New York license required (NY is not in IMLC for physicians or APRN compacts). No out-of-state telehealth license available.

Key Regulatory Notes:

• E-prescribing is mandatory for all prescriptions (since 2016)
• Use NY’s Prescription Monitoring Registry for controlled substances
• Telehealth parity laws require insurers to cover tele-mental health equivalently to in-person
• Audio-only allowed for behavioral health in many cases (especially Medicaid)

Economics: Dense provider network in NYC, but shortages upstate. Telepsychiatry is widely used to connect city specialists with rural patients. New York patients tend to have good insurance coverage, and the state actively supports expanding mental health access via telehealth. Marketing costs in NYC are high ($400+ per patient); upstate is somewhat lower but still $200–300+ per lead when doing it yourself.

Pennsylvania

Telehealth Prescribing: No permanent telehealth statute (legislation has failed multiple times), but the Department of State has made clear that providers can deliver care via telemedicine if it meets the standard of care. No state-level in-person exam requirement.

NP Scope: No full practice authority. PMHNPs need a collaborative agreement with a physician (typically a psychiatrist). Ongoing efforts to pass FPA legislation (e.g., SB 25) have not succeeded as of 2025.

Licensing: Full PA license required. Pennsylvania is an IMLC member (joined 2021), so out-of-state physicians can get a PA license more easily.

Key Regulatory Notes:

• E-prescribing mandatory for controlled substances (with limited exceptions)
• Check PA’s PDMP before prescribing controlled substances
• Obtain explicit patient consent for telehealth (document it)
• Pennsylvania has large rural areas with severe psychiatrist shortages—telepsychiatry is critical for access

Economics: High demand, especially in rural ‘Pennsyltucky’ counties. Medicaid reimburses telehealth equivalently to in-person. Patient acquisition via DIY marketing is challenging in rural areas (low search volume, high competition in metro areas). Platforms solve this by aggregating demand across the state and matching you with patients in underserved areas.

Illinois

Telehealth Prescribing: Illinois passed a comprehensive telehealth law in 2021 (Public Act 102-0104) ensuring payment parity and allowing telehealth from any location. No in-person exam mandate.

NP Independence: Full Practice Authority available after 4,000 hours of practice + 250 hours of additional education/training. PMHNPs with FPA can diagnose, treat, and prescribe (including controlled substances) independently.

Licensing: Full Illinois license required. Illinois is an IMLC member for physicians and has adopted the APRN Compact (not yet in effect pending additional member states).

Key Regulatory Notes:

• E-prescribing required for controlled substances
• FPA APRNs must have a physician consultation process for ongoing Schedule II opioid prescriptions (not typically relevant for psychiatric practice)
• Use Illinois Prescription Monitoring Program
• Audio-only allowed for behavioral health services

Economics: Most psychiatrists are in Chicago/Springfield; rural downstate Illinois is severely underserved. Telehealth parity law (2021) has boosted virtual visits significantly. Patient acquisition cost via Google Ads or SEO in Chicago is $300–500+; in rural areas, volume is too low to make DIY marketing viable. Platforms like Klarity solve this by matching you with patients statewide, avoiding wasted ad spend.

The Economics: Why Platforms Beat DIY Patient Acquisition

Let’s talk numbers. If you’re considering building your own telehealth practice, you’ve probably looked into marketing channels: Google Ads, SEO, Psychology Today, Zocdoc, etc.

Here’s the reality:

Google Ads:

• Mental health keywords cost $15–40+ per click
• Most clicks don’t convert to booked appointments (10–20% conversion rate if you’re good)
• Realistic cost per booked patient: $200–400+
• You need expertise to optimize campaigns, or you’re paying an agency $1,500–3,000/month to do it for you

SEO:

• Takes 6–12 months of consistent investment before generating meaningful patient flow
• Requires ongoing content creation, backlink building, technical optimization
• Most solo providers don’t have the expertise or patience for this
• Agency costs: $2,000–5,000+/month

Psychology Today:

• $29.95–39.95/month for a listing
• You compete with hundreds of other providers on the same search page
• Response rates are unpredictable—some providers get inquiries, many don’t
• No guarantee of qualified leads (plenty of tire-kickers and insurance mismatches)

Zocdoc:

• $275–349/month subscription (varies by market and specialty)
• Plus $35–100+ per new patient booking
• Total monthly cost including subscription easily hits $500–1,000+ for modest volume
• Better quality leads than PT, but you’re still paying upfront regardless of show rates

Total all-in cost when doing it yourself: $3,000–5,000+/month in ad spend, subscriptions, and agency fees, with zero guarantee of patient volume. If you’re starting out or scaling up, that’s a huge financial risk.

The Klarity model is fundamentally different:

• No upfront spend. No monthly subscriptions, no ad budget, no agency retainers.
• Pay only when a qualified patient books with you. Standard listing fee per new patient lead.
• Pre-qualified patients already matched to your specialty, state license, and availability.
• Built-in telehealth infrastructure—no separate platform costs (EHR, video, e-prescribing integrated).
• Insurance and cash-pay patients—you’re not limited to one payer type.
• You control your schedule—set your availability, and we fill the slots.

Instead of gambling $3,000–5,000/month on marketing channels with uncertain results, you pay a predictable per-appointment fee only when you see patients. That’s guaranteed ROI versus the hope-and-pray approach of DIY marketing.

Could you eventually build a cost-effective marketing funnel on your own? Sure—if you have the budget, expertise, and patience to optimize for 6–12 months. Most providers, especially those starting out or scaling, would rather spend that time seeing patients.

FAQ: Common Questions from Depression Providers

Q: Can I prescribe SSRIs to a patient I’ve never met in person via telehealth?

A: Yes, in every state (where you’re licensed). SSRIs are not controlled substances, so federal DEA rules don’t apply. As long as your telehealth encounter meets the standard of care (psychiatric evaluation, informed consent, documentation), you can prescribe antidepressants via video or phone (depending on state law).

Q: What about benzodiazepines for a patient with depression and anxiety?

A: Yes, under current federal rules (through December 31, 2026). Benzodiazepines are Schedule IV controlled substances, but the DEA’s COVID-era flexibilities allow you to prescribe them via telehealth without an initial in-person visit. After 2026, the rules may change—watch for the DEA’s final regulations on special telemedicine registrations.

Q: Can I prescribe Adderall via telehealth for a patient with depression and ADHD?

A: Yes, if you’re a psychiatrist and you’re treating a psychiatric disorder (ADHD qualifies). Current federal rules allow it through 2026. Some states (like Florida) explicitly permit Schedule II prescribing via telehealth for psychiatric conditions. After 2026, psychiatrists are expected to be able to apply for an ‘Advanced Telemedicine Prescribing’ registration to continue doing this.

If you’re a PMHNP, it depends on your state’s scope of practice. In full-practice states like California, New York, or Illinois (with FPA), you can prescribe Schedule II stimulants. In restricted states like Texas or Florida, you may need your supervising physician to prescribe, or you may only be able to prescribe in certain settings.

Q: Do I need to see the patient in person at any point?

A: Not under current federal law (through 2026). State laws vary, but most states allow telehealth-only patient relationships for psychiatric care. A few states have specific requirements (e.g., Texas requires video for new patients prescribing controlled substances, not phone-only).

Best practice: If a patient’s condition worsens or isn’t responding to treatment, consider whether an in-person evaluation or referral to a local provider is clinically appropriate—not because the law requires it, but because it’s good medicine.

Q: What about esketamine (Spravato) for treatment-resistant depression?

A: You can do the psychiatric evaluation via telehealth, but esketamine itself must be administered in a certified clinic under supervision due to FDA REMS requirements (patient can’t take it home). This is a pharmaceutical regulation, not a telemedicine law. You would manage the patient via telehealth but coordinate with a local clinic for the actual dosing sessions.

Q: If I’m licensed in multiple states, can I see patients in all of them via telehealth?

A: Yes, as long as you’re licensed (or hold a valid telehealth registration) in each patient’s state. The patient’s location determines which state’s laws apply—not yours. If you’re licensed in California, Texas, and Florida, you can see patients in all three states, following each state’s rules for those patients.

Q: I’m a PMHNP in Texas. Can I join Klarity and see patients independently?

A: Not independently—Texas requires a Prescriptive Authority Agreement with a physician. If you have a collaborating psychiatrist in Texas, you can see patients via Klarity (and the platform can help coordinate the collaboration paperwork). If you don’t have one yet, Klarity may be able to connect you with a supervising psychiatrist on the network.

Q: What happens after December 31, 2026?

A: The DEA is expected to finalize permanent rules before then. If the proposed rules from January 2025 are enacted, psychiatrists will be able to apply for a special telemedicine registration to continue prescribing controlled substances (including Schedule II) without in-person exams. PMHNPs and PAs may face more restrictions for Schedule II prescribing (or may need to work under a psychiatrist with the registration). Non-controlled medications (SSRIs, SNRIs, etc.) will remain unaffected.

Keep an eye on DEA announcements in late 2025 and 2026. Professional organizations (APA, AANP) will likely provide guidance once the final rules are published.

Ready to Expand Your Practice via Telehealth?

The regulatory environment for telepsychiatry is more favorable than it’s ever been—and it’s staying that way through at least 2026. Whether you’re a psychiatrist with full prescribing authority or a PMHNP navigating state-specific scope-of-practice rules, telehealth lets you reach more patients, work from anywhere, and avoid the overhead of a traditional office.

If you’re spending $3,000–5,000/month on marketing with unpredictable results, there’s a better way. Klarity Health connects psychiatrists and PMHNPs with pre-qualified patients who need depression treatment—no upfront marketing spend, no wasted ad budget, no tire-kickers. You pay only when a patient books with you, and we handle the infrastructure (telehealth platform, EHR, e-prescribing, insurance billing).

Sound interesting? Explore Klarity’s provider network and see how we can help you grow your practice—on your terms, in your licensed states, without the financial risk of DIY patient acquisition.

Questions about your state’s specific rules or how the platform works? Our provider team can walk you through the details and help you get started. Schedule a call or learn more about joining Klarity.

Citations & Sources

1. HHS Press Release – ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (January 2, 2026)
   https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html
   Official announcement of the fourth temporary extension of COVID-era DEA telehealth rules through December 31, 2026.

2. DEA Press Release – ‘DEA Announces Three New Telemedicine Rules to Continue Open Access to Telehealth’ (January 16, 2025)
   https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access
   Details on proposed permanent DEA telehealth rules, including special registrations for prescribing controlled substances via telemedicine.

3. Florida Statutes §456.47 – Use of Telehealth to Provide Services
   https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html
   Official Florida state law governing telehealth prescribing, including the psychiatric disorder exception for Schedule II controlled substances.

4. Texas Administrative Code Title 22, Part 9 §174.5 – Telemedicine Issuance of Prescriptions
   https://txrules.elaws.us/rule/title22chapter174sec.174.5
   Texas Medical Board regulation detailing telemedicine prescribing standards, including restrictions on chronic pain treatment via telehealth.

5. California AB 890 Implementation – California Board of Registered Nursing
   https://www.rn.ca.gov/practice/ab890.shtml
   Official information on California’s nurse practitioner independence law (AB 890), enabling PMHNPs to practice without physician supervision after meeting experience requirements.

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=These%20rules%20are%20a%20result,temporary%20rule%20until%20December%202025
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=is%20accessible%20for%20medical%20care,is%20being%20prescribed%20controlled%20medication
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=%2A%20103%20NP%20,focus%20of%20their%20National%20Certification
• https://www.rivkinrounds.com/2022/04/new-law-allows-experienced-nps-to-practice-independently-in-ny/#:~:text=New%20York%20law%20previously%20allowed,based%20on%20only
• https://txrules.elaws.us/rule/title22chapter174sec.174.5#:~:text=,person%20setting
• https://txrules.elaws.us/rule/title22chapter174sec.174.5#:~:text=,be
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://txrules.elaws.us/rule/title22chapter174sec.174.5#:~:text=,through%20a%20telemedicine%20medical%20service